{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T06:38:51Z","timestamp":1775025531466,"version":"3.50.1"},"reference-count":103,"publisher":"Elsevier BV","issue":"9317","license":[{"start":{"date-parts":[[2002,5,1]],"date-time":"2002-05-01T00:00:00Z","timestamp":1020211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2002,5,1]],"date-time":"2002-05-01T00:00:00Z","timestamp":1020211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet"],"published-print":{"date-parts":[[2002,5]]},"DOI":"10.1016\/s0140-6736(02)08520-3","type":"journal-article","created":{"date-parts":[[2002,10,11]],"date-time":"2002-10-11T08:03:50Z","timestamp":1034323430000},"page":"1589-1598","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":212,"title":["Treatment interventions for Parkinson's disease: an evidence based assessment"],"prefix":"10.1016","volume":"359","author":[{"given":"Olivier","family":"Rascol","sequence":"first","affiliation":[]},{"given":"Christopher","family":"Goetz","sequence":"additional","affiliation":[]},{"given":"William","family":"Koller","sequence":"additional","affiliation":[]},{"given":"Werner","family":"Poewe","sequence":"additional","affiliation":[]},{"given":"Cristina","family":"Sampaio","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/S0140-6736(02)08520-3_bib1","unstructured":"CG Goetz, WC Koller W, Poewe, et al. Management of Parkinson's disease: an evidence-based review. Mov Disorders (in press)."},{"key":"10.1016\/S0140-6736(02)08520-3_bib2","series-title":"Checklists for critical appraisal: the evidence based medicine workboo\u2014critical appraisal for clinical problem solving","author":"Dixon","year":"1997"},{"key":"10.1016\/S0140-6736(02)08520-3_bib3","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0166-2236(90)90110-V","article-title":"Primate models of movement disorders of basal ganglia origin","volume":"13","author":"DeLong","year":"1990","journal-title":"Trends Neurosci"},{"key":"10.1016\/S0140-6736(02)08520-3_bib4","first-page":"301","article-title":"Dopamine agonists: their role in the management of Parkinson's disease","volume":"86","author":"Rascol","year":"2001","journal-title":"Adv Neurol"},{"key":"10.1016\/S0140-6736(02)08520-3_bib5","first-page":"51","article-title":"The pharmacology of selegiline","volume":"9","author":"Johnson","year":"1992","journal-title":"Rev Contemp Pharmacol"},{"key":"10.1016\/S0140-6736(02)08520-3_bib6","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.2165\/00003495-200059060-00004","article-title":"Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease","volume":"59","author":"Kaakkola","year":"2000","journal-title":"Drugs"},{"key":"10.1016\/S0140-6736(02)08520-3_bib7","series-title":"Handbook of experimental pharmacology, volume 88: drugs for the treatment of Parkinson's diseases","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-642-73899-9_12","article-title":"Anticholinergic drugs and amantadine in the treatment of Parkinson's disease","author":"Lang","year":"1989"},{"key":"10.1016\/S0140-6736(02)08520-3_bib8","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1001\/archneur.1991.00530210109030","article-title":"N-methyl-D-aspartate antagonists in the treatment of Parkinson's disease","volume":"48","author":"Greenamyre","year":"1991","journal-title":"Arch Neurol"},{"key":"10.1016\/S0140-6736(02)08520-3_bib9","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1001\/archneur.57.8.1118","article-title":"Surgery for Parkinson disease: a critical evaluation of the state of the art","volume":"57","author":"Lang","year":"2000","journal-title":"Arch Neurol"},{"key":"10.1016\/S0140-6736(02)08520-3_bib10","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/0470870834.ch2","article-title":"Cell replacement strategies for neurodegenerative disorders","volume":"231","author":"Bjorklund","year":"2000","journal-title":"Novartis Found Symp"},{"key":"10.1016\/S0140-6736(02)08520-3_bib11","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1136\/jnnp.64.3.314","article-title":"Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with (18)fluorodopa-PET","volume":"64","author":"Morrish","year":"1998","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/S0140-6736(02)08520-3_bib12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2165\/00023210-199401010-00005","article-title":"Potential of neuroprotective therapy in Parkinson's disease","volume":"1","author":"Mizuno","year":"1994","journal-title":"CNS Drugs"},{"key":"10.1016\/S0140-6736(02)08520-3_bib13","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1146\/annurev.pharmtox.41.1.625","article-title":"Drug treatment effects on disease progression","volume":"41","author":"Chan","year":"2001","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/S0140-6736(02)08520-3_bib14","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1056\/NEJM198911163212004","article-title":"Effect of deprenyl on the progression of disability in early Parkinson's diseases","volume":"321","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(02)08520-3_bib15","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1056\/NEJM199301213280305","article-title":"Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease","volume":"328","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(02)08520-3_bib16","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/ana.410380512","article-title":"The effect of deprenyl and levodopa on the progression of Parkinson's disease","volume":"38","author":"Olanow","year":"1995","journal-title":"Ann Neurol"},{"key":"10.1016\/S0140-6736(02)08520-3_bib17","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2165\/00002018-199921050-00001","article-title":"Levodopa in Parkinson's disease. Neurotoxicity issue laid to rest?","volume":"21","author":"Murer","year":"1999","journal-title":"Drug Safety"},{"key":"10.1016\/S0140-6736(02)08520-3_bib18","first-page":"153","article-title":"Unified Parkinson's disease rating scale","volume":"2","author":"Fahn","year":"1987"},{"key":"10.1016\/S0140-6736(02)08520-3_bib19","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJM196902132800701","article-title":"Modification of parkinsonism: chronic treatment with levodopa","volume":"280","author":"Cotzias","year":"1969","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(02)08520-3_bib20","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1136\/bmj.307.6902.469","article-title":"Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report","volume":"307","year":"1993","journal-title":"BMJ"},{"key":"10.1016\/S0140-6736(02)08520-3_bib21","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/mds.870130111","article-title":"Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study","volume":"13","author":"Rascol","year":"1998","journal-title":"Mov Disord"},{"key":"10.1016\/S0140-6736(02)08520-3_bib22","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1001\/jama.284.15.1931","article-title":"Pramipexole versus levodopa as initial treatment for Parkinson's disease: a randomized controlled trial","volume":"284","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/S0140-6736(02)08520-3_bib23","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1212\/WNL.53.5.1012","article-title":"Immediate-release and controlled-release carbidopa\/levodopa in PD: a 5-year randomized multicenter study","volume":"53","author":"Koller","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/S0140-6736(02)08520-3_bib24","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1034\/j.1600-0404.2000.90295a.x","article-title":"Alpha-dihydroergocryptine in the treatment of de novo parkinsonian patients: results of a multicentre, randomised, double-blind, placebo-controlled study","volume":"101","author":"Bergamasco","year":"2000","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/S0140-6736(02)08520-3_bib25","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1212\/WNL.53.3.573","article-title":"Pergolide monotherapy in the treatment of early Parkinson's disease: a randomized, controlled study","volume":"53","author":"Barone","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/S0140-6736(02)08520-3_bib26","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1212\/WNL.49.3.724","article-title":"Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease","volume":"49","author":"Shannon","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/S0140-6736(02)08520-3_bib27","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1212\/WNL.49.2.393","article-title":"Ropinirole for the treatment of early Parkinson's disease","volume":"49","author":"Adler","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/S0140-6736(02)08520-3_bib28","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/ana.410390106","article-title":"Impact of deprenyl and tocopherol treatment of Parkinson's disease in DATATOP subjects not requiring levodopa","volume":"39","year":"1996","journal-title":"Ann Neurol"},{"key":"10.1016\/S0140-6736(02)08520-3_bib29","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1212\/WNL.39.3.336","article-title":"Lisuride, a dopamine agonist in the treatment of early Parkinson's disease","volume":"39","author":"Rinne","year":"1989","journal-title":"Neurology"},{"key":"10.1016\/S0140-6736(02)08520-3_bib30","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1212\/WNL.36.2.291","article-title":"Low dose bromocriptine therapy in Parkinson's disease: double-blind, placebo-controlled, crossover study","volume":"36","author":"Staal-Schreinemachers","year":"1986","journal-title":"Neurology"},{"key":"10.1016\/S0140-6736(02)08520-3_bib31","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1212\/WNL.25.7.603","article-title":"Amantadine in Parkinson's disease: a double-blind, placebo-controlled, crossover study with long-term follow-up","volume":"25","author":"Butzer","year":"1975","journal-title":"Neurology"},{"key":"10.1016\/S0140-6736(02)08520-3_bib32","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1093\/brain\/115.6.1701","article-title":"Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease","volume":"115","author":"Cooper","year":"1992","journal-title":"Brain"},{"key":"10.1016\/S0140-6736(02)08520-3_bib33","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1212\/WNL.49.4.1060","article-title":"Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease","volume":"49","author":"Guttman","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/S0140-6736(02)08520-3_bib34","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1212\/WNL.46.4.1062","article-title":"Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease","volume":"46","author":"Hutton","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/S0140-6736(02)08520-3_bib35","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/mds.870090107","article-title":"A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease","volume":"9","author":"Olanow","year":"1994","journal-title":"Mov Disord"},{"key":"10.1016\/S0140-6736(02)08520-3_bib36","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1136\/jnnp.66.4.436","article-title":"Efficacy, safety and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: double-blind, placebo-controlled, randomized, multicenter study","volume":"66","author":"Pinter","year":"1999","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/S0140-6736(02)08520-3_bib37","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1212\/WNL.49.3.665","article-title":"Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment","volume":"49","author":"Waters","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/S0140-6736(02)08520-3_bib38","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1001\/archneur.55.8.1089","article-title":"Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson's disease treated with levodopa-carbidopa","volume":"55","author":"Adler","year":"1998","journal-title":"Arch Neurol"},{"key":"10.1016\/S0140-6736(02)08520-3_bib39","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1212\/WNL.51.5.1309","article-title":"Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations","volume":"51","author":"Rinne","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/S0140-6736(02)08520-3_bib40","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1212\/WNL.38.7.1143","article-title":"Controlled release long-acting levodopa\/carbidopa combination in Parkinson's disease patients with and without motor fluctuation","volume":"38","author":"Goetz","year":"1988","journal-title":"Neurology"},{"key":"10.1016\/S0140-6736(02)08520-3_bib41","first-page":"96","article-title":"Double-blind comparison of standard Sinemet and Sinemet CR in patients with mild-to-moderate Parkinson's disease","volume":"39","author":"Feldman","year":"1989","journal-title":"Neurology"},{"key":"10.1016\/S0140-6736(02)08520-3_bib42","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0364-7722(82)80107-0","article-title":"Parkinson's disease: Cogentin with Sinemet, a better response","volume":"6","author":"Wallace","year":"1982","journal-title":"Prog Neuro Psychopharmacol Biol Psychiatry"},{"key":"10.1016\/S0140-6736(02)08520-3_bib43","first-page":"605","article-title":"Amantadine and a fixed combination of levodopa and carbidopa in the treatment of Parkinson's disease","volume":"38","author":"Savery","year":"1977","journal-title":"Dis Nerv Syst"},{"key":"10.1016\/S0140-6736(02)08520-3_bib44","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1001\/archneur.58.9.1385","article-title":"A randomised double-blind placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-stat events","volume":"58","author":"Dewey","year":"2001","journal-title":"Arch Neurol"},{"key":"10.1016\/S0140-6736(02)08520-3_bib45","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000008188","article-title":"Five-year follow-up of early lisuride and levodopa combination therapy versus levodopa monotherapy in de novo Parkinson's disease","volume":"44","author":"Allain","year":"2000","journal-title":"Europ Neurology"},{"key":"10.1016\/S0140-6736(02)08520-3_bib46","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(99)03556-4","article-title":"Unilateral pallidotomy in Parkinson's disease: a randomized, single-blind, multicenter trial","volume":"354","author":"De Bie","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(02)08520-3_bib47","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/ana.410310206","article-title":"Transplantation of fetal dopamine neurons in Parkinson's disease: one-year clinical and neuropsychological observations in two patients with putaminal implants","volume":"31","author":"Lindvall","year":"1992","journal-title":"Ann Neurol"},{"key":"10.1016\/S0140-6736(02)08520-3_bib48","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1056\/NEJM199211263272201","article-title":"Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson's disease","volume":"327","author":"Spencer","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(02)08520-3_bib49","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1006\/exnr.1997.6577","article-title":"Outcome following intrastriatal fetal mesencepahalic grafts for Parkinson's patients is directly related to the volume of grafted tissue","volume":"146","author":"Kopyov","year":"1997","journal-title":"Exp Neurol"},{"key":"10.1016\/S0140-6736(02)08520-3_bib50","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1056\/NEJM200103083441002","article-title":"Transplantation of embryonic dopamine neurons for severe parkinson's disease","volume":"344","author":"Freed","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(02)08520-3_bib51","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1227\/00006123-199510000-00011","article-title":"Outcome after stereotactic thalamotomy for parkinsonian, essential and other types of tremor","volume":"37","author":"Jankovic","year":"1995","journal-title":"Neurosurgery"},{"key":"10.1016\/S0140-6736(02)08520-3_bib52","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1056\/NEJM200002173420703","article-title":"A comparison of continuous thalamic stimulation and thalamotomy for suppression of severe tremor","volume":"342","author":"Schuurman","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(02)08520-3_bib53","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1097\/00006123-199912000-00024","article-title":"Comparison of pallidal and subthalamic nucleus deep brain stimulation for advanced Parkinson's disease: results of randomized, blinded pilot study","volume":"45","author":"Burchiel","year":"1999","journal-title":"Neurosurgery"},{"key":"10.1016\/S0140-6736(02)08520-3_bib54","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1056\/NEJMoa000827","article-title":"Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease","volume":"345","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(02)08520-3_bib55","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1136\/jnnp.66.3.289","article-title":"Multicentre European study of thalamic stimulation in parkinsonian and essential tremor","volume":"66","author":"Limousin","year":"1999","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/S0140-6736(02)08520-3_bib56","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1212\/WNL.52.9.1908","article-title":"Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole","volume":"52","author":"Frucht","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/S0140-6736(02)08520-3_bib57","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/S0140-6736(00)02119-X","article-title":"Sleep attacks and Parkinson's disease treatment","volume":"355","author":"Ferreira","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(02)08520-3_bib58","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s004150170188","article-title":"Levodopa monotherapy can induce \"sleep attacks\" in Parkinson's disease patients","volume":"248","author":"Ferreira","year":"2001","journal-title":"J Neurol"},{"key":"10.1016\/S0140-6736(02)08520-3_bib59","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/mds.1083","article-title":"Sudden daytime sleep onset in Parkinson's disease: polysomnographic recordings","volume":"16","author":"Tracik","year":"2001","journal-title":"Mov Disorders"},{"key":"10.1016\/S0140-6736(02)08520-3_bib60","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1056\/NEJM200005183422004","article-title":"A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa","volume":"342","author":"Rascol","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(02)08520-3_bib61","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/mds.870130112","article-title":"Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: 6-month interim report of a 3-year study","volume":"13","author":"Korczyn","year":"1998","journal-title":"Mov Disord"},{"key":"10.1016\/S0140-6736(02)08520-3_bib62","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/1531-8257(199901)14:1<38::AID-MDS1008>3.0.CO;2-I","article-title":"Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated parkinsonian patients","volume":"14","year":"1999","journal-title":"Mov Disord"},{"key":"10.1016\/S0140-6736(02)08520-3_bib63","first-page":"79","article-title":"Pleuropulmonary fibrosis due to bromocriptine tratment for Parkinson's disease","volume":"27","author":"Todman","year":"1990","journal-title":"Clin Exp Neurol"},{"key":"10.1016\/S0140-6736(02)08520-3_bib64","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1742-1241.2000.tb11931.x","article-title":"Pergolide-induced retroperitoneal fibrosis","volume":"54","author":"Mondal","year":"2000","journal-title":"Int J Clin Pract"},{"key":"10.1016\/S0140-6736(02)08520-3_bib65","series-title":"Parkinson's disease and movement disorders","author":"Jankovic","year":"1998"},{"key":"10.1016\/S0140-6736(02)08520-3_bib66","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/00002826-200003000-00003","article-title":"A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia","volume":"23","author":"Hausser","year":"2000","journal-title":"Clin Neuropharmacol"},{"issue":"suppl 1","key":"10.1016\/S0140-6736(02)08520-3_bib67","first-page":"48","article-title":"Rating scales for dyskinesia in Parkinson's disease","volume":"14","author":"Goetz","year":"1999","journal-title":"Mov Disord"},{"key":"10.1016\/S0140-6736(02)08520-3_bib68","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/00002826-199619030-00005","article-title":"Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease","volume":"19","author":"Rascol","year":"1996","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/S0140-6736(02)08520-3_bib69","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1212\/WNL.51.4.1057","article-title":"A multicenter trial of ropinirole adjunct treatment for Parkinson's disease","volume":"51","author":"Lieberman","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/S0140-6736(02)08520-3_bib70","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1212\/WNL.48.1.81","article-title":"Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease with the \"wearing-off\" phenomenon: a double-blind, placebo-controlled, multicenter trial","volume":"48","author":"Kurth","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/S0140-6736(02)08520-3_bib71","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/jnnp.60.1.36","article-title":"Entacapone prolongs levodopa response in a one-month double-blind study in parkinsonian patients with levodopa related fluctuations","volume":"60","author":"Ruottinen","year":"1996","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/S0140-6736(02)08520-3_bib72","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1136\/jnnp.58.6.681","article-title":"Pen injected apomorphine against off phenomena in late Parkinson's disease: a double blind, placebo controlled study","volume":"58","author":"Ostergaard","year":"1995","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/S0140-6736(02)08520-3_bib73","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1212\/WNL.50.5.1323","article-title":"Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease","volume":"50","author":"Verhagen-Metman","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/S0140-6736(02)08520-3_bib74","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1001\/archneur.56.11.1383","article-title":"Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study","volume":"56","author":"Verhagen-Metman","year":"1999","journal-title":"Arch Neurol"},{"key":"10.1016\/S0140-6736(02)08520-3_bib75","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/00002826-200003000-00004","article-title":"The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study","volume":"23","author":"Snow","year":"2000","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/S0140-6736(02)08520-3_bib76","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/1531-8257(200009)15:5<873::AID-MDS1017>3.0.CO;2-I","article-title":"Beneficial effects of amantadine on levodopa-induced dyskinesia in Parkinson's disease","volume":"15","author":"Luginger","year":"2000","journal-title":"Mov Disorders"},{"key":"10.1016\/S0140-6736(02)08520-3_bib77","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1212\/WNL.50.2.434","article-title":"Stereotactic pallidotomy for the treatment of Parkinson's disease: efficacy and adverse effects at 6-months in 26 patients","volume":"50","author":"Shannon","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/S0140-6736(02)08520-3_bib78","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1136\/jnnp.64.5.573","article-title":"Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesia in Parkinson's disease","volume":"64","author":"Colzi","year":"1998","journal-title":"J Neurol Neurosug Psychiatry"},{"issue":"suppl","key":"10.1016\/S0140-6736(02)08520-3_bib79","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/S1471-1931(00)00030-6","article-title":"Continuous dopamine-receptor stimulation in early Parkinson's disease","volume":"23","author":"Olanow","year":"2000","journal-title":"Trends Neurosci"},{"issue":"suppl 1","key":"10.1016\/S0140-6736(02)08520-3_bib80","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2165\/00003495-199855001-00004","article-title":"Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications","volume":"55","author":"Rinne","year":"1998","journal-title":"Drugs"},{"key":"10.1016\/S0140-6736(02)08520-3_bib81","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1136\/jnnp.57.8.903","article-title":"The Sydney multicentre study of Parkinson's disease: a randomized, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa","volume":"57","author":"Hely","year":"1994","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/S0140-6736(02)08520-3_bib82","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1136\/jnnp.57.9.1034","article-title":"A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow-up","volume":"57","author":"Montastruc","year":"1994","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/S0140-6736(02)08520-3_bib83","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/BF01271230","article-title":"Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects: long-term results of the PRADO study","volume":"103","author":"Przuntek","year":"1996","journal-title":"J Neural Transm"},{"key":"10.1016\/S0140-6736(02)08520-3_bib84","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/00002826-199702000-00008","article-title":"Early combination of bromocriptine and levodopa in Parkinson's disease: a prospective randomized study of two parallel groups over a total follow-up period of 44 months including an initial 8-month double-blind stage","volume":"20","author":"Gimenez-Roldan","year":"1997","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/S0140-6736(02)08520-3_bib85","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1212\/WNL.53.2.364","article-title":"A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease","volume":"53","author":"Korczyn","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/S0140-6736(02)08520-3_bib86","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1600-0404.1996.tb00163.x","article-title":"Sustained-release Madopar HBS compared with standard Madopar in the long-term treatment of de novo parkinsonian patients","volume":"93","author":"Dupont","year":"1996","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/S0140-6736(02)08520-3_bib87","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000117399","article-title":"Comparison of immediate-release and controlled release carbidopa\/levodopa in Parkinson's disease: a multicenter 5-year study","volume":"37","author":"Block","year":"1997","journal-title":"Eur Neurol"},{"key":"10.1016\/S0140-6736(02)08520-3_bib88","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1001\/archneur.1992.00530290076015","article-title":"A population-based investigation of Parkinson's disease with and without dementia: relationship to age and gender","volume":"49","author":"Mayeux","year":"1992","journal-title":"Arch Neurol"},{"key":"10.1016\/S0140-6736(02)08520-3_bib89","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1212\/WNL.47.5.1113","article-title":"Consensus guidelines for the clinical and pathological diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop","volume":"47","author":"McKeith","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/S0140-6736(02)08520-3_bib90","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(00)03399-7","article-title":"Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study","volume":"356","author":"McKeith","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(02)08520-3_bib91","first-page":"115","article-title":"Parkinson's disease: drug-induced psychiatric states","volume":"65","author":"Factor","year":"1995","journal-title":"Adv Neurol"},{"key":"10.1016\/S0140-6736(02)08520-3_bib92","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1056\/NEJM199903113401003","article-title":"Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease","volume":"340","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(02)08520-3_bib93","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/S0140-6736(99)00860-0","article-title":"Clozapine in drug-induced psychosis in Parkinson's disease","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(02)08520-3_bib94","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1212\/WNL.55.6.789","article-title":"Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients","volume":"55","author":"Goetz","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/S0140-6736(02)08520-3_bib95","first-page":"3","article-title":"Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry","volume":"59","author":"Honigfeld","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/S0140-6736(02)08520-3_bib96","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2165\/00023210-200014020-00006","article-title":"Quetiapine: a review of its clinical potential in the management of psychotis symptoms in Parkinson's disease","volume":"14","author":"Matheson","year":"2000","journal-title":"CNS Drugs"},{"key":"10.1016\/S0140-6736(02)08520-3_bib97","first-page":"373","article-title":"Depression in Parkinson's disease: an update","volume":"86","author":"Oertel","year":"2001","journal-title":"Adv Neurol"},{"key":"10.1016\/S0140-6736(02)08520-3_bib98","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1600-0404.1980.tb03028.x","article-title":"Antidepressive treatment in Parkinson's disease: a controlled trial of the effect of nortriptyline in patients with Parkinson's disease treated with L-Dopa","volume":"62","author":"Andersen","year":"1980","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/S0140-6736(02)08520-3_bib99","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1136\/jnnp.63.4.547","article-title":"Moclobemide and selegeline in the treatment of depression in Parkinson's disease","volume":"63","author":"Steur","year":"1997","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/S0140-6736(02)08520-3_bib100","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1136\/jnnp.63.5.584","article-title":"Prevalence of orthostatic hypotension in Parkinson's disease","volume":"63","author":"Senard","year":"1997","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/S0140-6736(02)08520-3_bib101","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/0002-9343(93)90230-M","article-title":"Neurogenic orthostatic hypotension: a double-blind, placebo controlled study with midodrine","volume":"95","author":"Jankovic","year":"1993","journal-title":"Am J Med"},{"key":"10.1016\/S0140-6736(02)08520-3_bib102","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1001\/jama.1997.03540370036033","article-title":"Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension: a randomized, placebo-controlled multicenter study","volume":"277","author":"Low","year":"1997","journal-title":"JAMA"},{"key":"10.1016\/S0140-6736(02)08520-3_bib103","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000169827","article-title":"A controlled study with Dihydergot on patients with orthostatic dysregulation","volume":"61","author":"Lubke","year":"1976","journal-title":"Cardiology"}],"container-title":["The Lancet"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0140673602085203?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0140673602085203?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T23:48:29Z","timestamp":1758844109000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0140673602085203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,5]]},"references-count":103,"journal-issue":{"issue":"9317","published-print":{"date-parts":[[2002,5]]}},"alternative-id":["S0140673602085203"],"URL":"https:\/\/doi.org\/10.1016\/s0140-6736(02)08520-3","relation":{},"ISSN":["0140-6736"],"issn-type":[{"value":"0140-6736","type":"print"}],"subject":[],"published":{"date-parts":[[2002,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment interventions for Parkinson's disease: an evidence based assessment","name":"articletitle","label":"Article Title"},{"value":"The Lancet","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S0140-6736(02)08520-3","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2002 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}